Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Gain Therapeutics (GANX).
Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its pioneering Phase 1 study for GT-02287, a promising new treatment for Parkinson’s Disease, with no serious adverse events or discontinuations reported. This milestone, announced on July 9, 2024, represents a key advancement in the development of novel therapies for neurological conditions, potentially signaling hope for patients and investors alike.
See more insights into GANX stock on TipRanks’ Stock Analysis page.
